Boule Diagnostics proposes a massive 3-for-1 rights issue and a directed share issuance to address debt obligations and bolster liquidity, with an EGM set for December 7, 2026.
The board decided on 4 November 2026 to a rights issue of up to 116,499,312 new shares, with 3 new shares for every 1 existing share, to be approved at an EGM on 7 December 2026. The high dilution ratio, combined with related-party loans carrying 10% annual interest, points to balance-sheet stress and weighs on the share price.
Each existing share entitles the holder to one subscription right, and one subscription right gives the right to subscribe for three new shares, according to the proposed terms.
The extraordinary general meeting is scheduled for 7 December 2026 at 10:00 in the company's premises in Spånga.
Boule Diagnostics AB has scheduled an extraordinary general meeting for December 7, 2026, to seek shareholder approval for a major rights issue of up to 116.5 million shares. The capital raise, featuring a 3-for-1 subscription ratio, aims to strengthen the company's balance sheet through debt-for-equity swaps with major stakeholders and external investors.
The rights issue is intended to strengthen the company's financial position and allow for the conversion of existing debt into equity, thereby reducing interest-bearing liabilities.
The extraordinary general meeting is scheduled to take place on December 7, 2026, at 10:00 in the company's premises in Spånga.